# Effect of an Electronic Reminder System on Direct Oral Anticoagulant and Oral Diabetes Medication Adherence

Study · id `cardio:ct-nct03753568` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03753568](<https://clinicaltrials.gov/study/NCT03753568>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03753568

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT03753568. Allocation not applicable; no masking; primary purpose treatment. Start 2019-03-20 (actual); primary completion 2019-07-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT03753568, source copy `cardio:ctgov-nct03753568-2019-03-25`, retrieved 2026-10-26)
- Started: 2019-03-20 (actual) (ClinicalTrials.gov record NCT03753568, source copy `cardio:ctgov-nct03753568-2019-03-25`, retrieved 2026-10-26)
- Primary completion: 2019-07-30 (anticipated) (ClinicalTrials.gov record NCT03753568, source copy `cardio:ctgov-nct03753568-2019-03-25`, retrieved 2026-10-26)
- Completion: 2019-09-01 (anticipated) (ClinicalTrials.gov record NCT03753568, source copy `cardio:ctgov-nct03753568-2019-03-25`, retrieved 2026-10-26)
- Countries: Finland (ClinicalTrials.gov record NCT03753568, source copy `cardio:ctgov-nct03753568-2019-03-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03753568-2019-03-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of an Electronic Reminder System on Direct Oral Anticoagulant and Oral Diabetes Medication Adherence
- Condition: Anticoagulant Drugs
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): Electronic medicine reminder system
- Lead sponsor: Helsinki University Central Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Helsinki University Central Hospital (`cardio:org-helsinki-university-central-hospital`)

## Provenance

Content hash: 77a2882f60b773f9e2bc8036dff05e7b68932b252b2c2de9abfd3ae9a0c1050f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
